Off-label use of dupilumab for the treatment of moderate to severe atopic dermatitis in children aged below 6 years of age: a case series

Clin Exp Dermatol. 2022 Feb;47(2):423-425. doi: 10.1111/ced.14925. Epub 2021 Oct 19.

Authors

J Da¹, K Ali², K Lu³, H Lou², Y Qiu², J Shan², L Wu¹

Affiliations

¹ Department of, Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
³ Department of, Oncological Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

PMID: 34482550
DOI: 10.1111/ced.14925

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Child, Preschool
Dermatitis, Atopic / drug therapy*
Drug Therapy, Combination
Female
Histamine Antagonists / therapeutic use
Humans
Interleukin-4 Receptor alpha Subunit / antagonists & inhibitors*
Male
Off-Label Use*

Substances

Antibodies, Monoclonal, Humanized
Histamine Antagonists
Interleukin-4 Receptor alpha Subunit
dupilumab